ClearPoint Neuro Inc. (CLPT)
NASDAQ (CM) NASDAQ (CM) Primary 
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth.
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago.
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
ClearPoint Neuro: Near-Term Volatility Is No Concern
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution.
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago.
ClearPoint Neuro Reports Third Quarter 2024 Results
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024. Third Quarter Highlights Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase; Overall product revenue, including biologics and drug delivery, more than doubled year-over-year, growing 127% to $5.5 million; Activated five new global centers in the third quarter for a total of 19 new centers so far this year; approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt as of September 30, 2024; Quarterly operational cash burn reduced to $1.2 million, a 33% year-over-year decrease; and Reported cash and cash equivalents totaling $21.6 million as of September 30, 2024.
ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock?
ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)
ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data.
